AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

AGREEMENT

Between

BioCancell Therapeutics Ltd.

Xxxx Science Center, 0 Xxxxxx Xx.

Xxxxxxxxx 00000, Xxxxxx

(Hereinafter: “BioCancell”)

And between

Medical Research Infrastructure Development and Health Services Fund by Xxxxx Sheba Fund, a non profit organization incorporated under the Laws of the State of Israel, represented by its authorized representative (the “Fund”);

BioCancell and the Fund shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.

Whereas		BioCancell has expressed its interest in carrying out, managing and funding the clinical trial the subject of which being “Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients with Intermediate-Risk Superficial Bladder Cancer”, bearing protocol no. BC-07-01, a copy of which is attached as Appendix A hereto (hereinafter: “the Trial”); and
Whereas		The Fund agrees to carryout the Study, employing the services of the Investigator;
Whereas		The Fund has declared it holds the proper facilities and staff required to perform the Trial, and that it is willing to put such facilities and staff at the disposal of BioCancell, for the purpose of performing the Trial; and
Whereas		The Parties agree that BioCancell shall maintain any and all management authorities with regard to the performance of the Trial in all of its stages; and
Whereas		BioCancell has agreed to pay the Fund the consideration, specified in Appendix C hereto, for the performance of all the undertakings of the Fund under this Agreement; all, according to the terms and conditions of this Agreement

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

NOW, THEREFORE, it is hereby declared and agreed between the parties as follows:

1. General

1.1. The preface and appendices to this Agreement constitute an integral part hereof.

1.2. Titles of the sections in this Agreement shall be used for terms of reference only, and could not be used for the interpretation of this Agreement.

1.3. This Agreement contains the entire understanding of the Parties and the Principle Investigator with respect to the subject matter hereof, and supersedes all prior or pre-existing negotiations, declarations, presentations, commitments and/or agreements, whether written or oral, whether explicit or implied, between the Parties and the Principle Investigator, with respect to such subject matter.

1.4. In the event of a contradiction between this Agreement and any of the terms of its appendices, the terms and conditions of this Agreement shall prevail.

1.5. Anything in this Agreement denoting the singular shall also denote the plural, and anything denoting the feminine gender shall also denote the masculine gender, and vice versa, insofar as no other meaning is inferred by the context.

2.  Appendices

The appendices to the Agreement are:

2.1. Appendix A: The Trial Protocol

2.2. Appendix B: The Trial Personnel Clearance

2.3. Appendix C: The Consideration

2.4. Appendix D: Schedule 4 of the Guidelines.

2.5. Appendix E: The Trial Documents and Related Activities.

3. Definitions

In this Agreement, the following terms shall have the specific meaning attributed to them in the table below:

The Agreement		This agreement and its appendices.
Serious Adverse Event		As defined in the Trial Protocol and in the Guidelines.
Monitors		Any body or person/s nominated by, or representing BioCancell and/or any company of the BioCancell Group to monitor the Trial (i.e., conduct on-site audits for Good Clinical Practices compliance).
Completed CRF		A CRF having, according to the sole and absolute discretion of BioCancell and/or any third party appointed by BioCancell, no discrepancies in its details and no unanswered queries.
CRF		Case Report Forms containing any and all data of the Subjects, which has been gathered during the Trial. The CRF shall be in hardcopy format.
The End of the Trial		The point in time, in which a Completed CRF has been submitted to BioCancell by the Principal Investigator, as defined herein, for all the Subjects participating in the Trial, or the date of termination of the Trial according to the terms and conditions of the Agreement; the earlier of the two.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

FDA The Guidelines		The United States of America Food and Drug Administration.  Ministry of Health guidelines entitled “Clinical Trials of Human Subjects” as may be amended and modified from time to time.
The Helsinki Declaration		The 1964 Declaration of Helsinki regarding the recommendations guiding physicians in bio-medical research involving human beings, as amended in Tokyo, 1975.
ICH-GCP		Harmonized Tripartite Guideline for Good Clinical Practice as may be amended and modified from time to time.
IND		Investigational New Drug Application (US code of Federal Regulations 21 CFR Part 312).
Inspector/s		Any inspecting body legally authorized to perform inspections in clinical trials, including, inter alia, the MOH. FDA or any other state regulated medical authority.
Invention Rights		Any and all intellectual property rights, relating to the Trial Data or to the BioCancell Data, including, inter alia, the right to register and/or own any inventions stemming directly or indirectly from the Trial Data and/or the BioCancell Data. Without derogating from the generality of the above, the Invention Rights shall include, inter alia, parents, information, data,  know-how, formulas, concepts, tests, drawings, specifications, applications, designs and trade secrets, methodologies, engineering and manufacturing processes and research processes, stemming directly or indirectly from the BioCancell Data and/or the Trial Data.
Investigator Brochure		A document, which is submitted along with the Trial Protocol to the relevant Helsinki Committee and FDA, and the content of which is outlined in the GCP Guidelines.
The Medical Center		Xxxxx Sheba Medical Center.
Medical Center Helsinki Committee Ministry of Health Approval		A committee appointed pursuant to the National Health Regulations and whose role is to approve any and all medical experiments on humans conducted by the Medical Center. Approval from the Director General of the Ministry of Health, or whomever he/she has delegated the authority to for this purpose, for the performance of the Trial at the Medical Center, according to the National Health Regulations and the Guidelines.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Ministry of Health / MOH		The Israeli Ministry of Health.
National Health Regulations		Israel National Health Regulations (Clinical Trials on Human Subjects), 5741-1980 as may be amended from time to time.
Publications		All publications, manuscripts, abstracts and papers relating directly or indirectly to the subject matter of the Trial, and which were initiated or composed directly or indirectly, in whole or in part, by the Principal Investigator and/or by the Fund and/or by any of the Trial Personnel.
The BioCancell Data		Any and all information provided by BioCancell or by the BioCancell Group to the Fund, Principal Investigator or any member of the Trial Personnel with regard to the Trial, including, without limitation, the Trial Protocol and the Investigator Brochure which shall be the sole property of the BioCancell Group.
The BioCancell Group		The group of companies consisting of BioCancell Therapeutics, Inc and BioCancell Therapeutics Ltd.
The Guidelines		Ministry of Health guidelines entitled “Clinical Trials of Human Subjects” as may be amended and modified from time to time.
The Product(s)		DTA-H19/PEI
The Reports		Any and all reports required by BioCancell, by any state regulated medical authority, or by any applicable laws, rules, regulations or guidelines.
The Subjects		A group of persons chosen by the Principal Investigator to participate in the Trial and who signed a written informed consent for the participation in the Trial, all according to the criteria established in the Trial Protocol.
The Trial Data		Any and all clinical data, technical information, records, files and materials relating to the Trial, including the Trial Documents, case report forms, (such as subjects charts and physical notes), as well as other related data generated during or as a result of the Trial which shall be the sole property of the BioCancell Group.
Trial Documents		Any and all documents required by BioCancell, the MOH, the Fund or any applicable laws, rules, regulations or guidelines, for the initiation, performance and completion of the Trial; without derogating from the generality of the above, the Trial Documents shall include any and all documents specified in Appendix E to this Agreement.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Trial Personnel		The medical and administrative staff involved in the Trial, including those who shall be employed by the Medical Center and/or the Fund and cleared according to the undertaking attached to this Agreement as Appendix B.
The Trial Protocol		A document that describes the objective(s), design, methodology, statistical considerations, and organization of the Trial. The Trial Protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout this Agreement the term Trial Protocol refers to the protocol and its amendments, which are attached to this Agreement as Appendix A.

4. Precedent Condition

The Parties hereby agree and undertake that the Agreement shall not enter into effect before both of following cumulative approvals have been granted (hereinafter: “the Approvals”):

4.1. The approval of the Trial Protocol by the Medical Center Helsinki Committee and the MOH, if such latter approval is required by the Guidelines; and

4.2. The approval of the Agreement in general, its budget and Appendix C in particular, by the MOH and the committee of engagement with commercial companies in accordance Section 9 of the Guidelines; and

4.3. The approval of the Trial Protocol, Investigator Brochure and related documents by the FDA

5. The Principal Investigator

5.1. Xxxxx X. Xxxxx MD, PhD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial

5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA

5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above.

5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Fund shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Fund not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Fund and/or any third party acting on their behalf in direct or indirect connection with such replacement.

6. Fund undertaking

6.1. The Fund represents that it has the requisite skills, knowledge, experience and human resources to undertake and conduct the Trial in accordance with the provisions of this Agreement

6.2. The Fund undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in  Israel, and (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time.

6.3. The Medical Center hereby undertakes to furnish BioCancell, the Principal Investigator and all of the Trial Personnel with the facilities and personnel necessary for the adequate performance of the Trial according to the terms and conditions of the Trial Protocol, and to fully collaborate with the Principal Investigator, BioCancell, and/or any other third party nominated by BioCancell, with regard to performing its duties hereunder.

7. BioCancell Undertaking

7.1. BioCancell hereby undertakes to allow the Principal Investigator to use the BioCancell Data, exclusively for the purpose of performing the Trial, during the Term of This Agreement and according to the terms and conditions of this Agreement.

The Principal Investigator shall strictly abide by any and all instructions given to him by BioCancell with regard to the BioCancell Data, while recognizing that BioCancell or any other company from the BioCancell Group was and shall remain, during the Term of this Agreement and thereafter, the sole and exclusive owner of any and all rights in the BioCancell Data and the Trial Data, and the use thereof.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

7.2. BioCancell shall remunerate the Fund, according to the terms of Appendix C hereto, for all services rendered.

8. Consideration

In consideration for the performance of all of the tasks, duties and undertakings of the Principal Investigator, the Trial Personnel and the Fund under this Agreement, BioCancell hereby undertakes to pay the Fund the amount specified in Appendix C hereto, according to the installments, timetable and manner specified therein.

9. Product Supply

9.1. BioCancell will, at its own expense, supply to the Fund all necessary quantities of the drugs to be used in the Trial, and only for the purposes as described in the Protocol. Any surplus shall be returned to BioCancell without delay, upon completion of the Trial or termination of this agreement for any reason whichever is the earlier.

9.2. The Fund will ensure that the Product is managed and stored in accordance with GCP and with any special instructions issued by BioCancell. The Fund will maintain proper records of receipts, dispensing and returns of the Product.

9.3. BioCancell will continue to supply the Product after the termination of the Trial and/or Agreement to the patients participating in the trial in accordance with Appendix D.

10. Trial Personnel Compliance and Clearance

10.1. The Fund and the Principal Investigator hereby undertake to exercise their best efforts so that the Trial Personnel shall abide by: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Fund Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, and (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time.

10.2. The Trial will also be conducted in accordance with the “Statement of Investigator” (FDA form no. 1572).

10.3. Trial Personal Clearance:

10.3.1. The Fund and the Principal Investigator shall deploy all possible efforts to see to it that none of the Trial Personnel (including the Principal Investigator and any other investigators) are debarred by the FDA or by the MOH in any capacity whatsoever, and that (1) none of the Trial Personnel appear in the FDA debarment list, detailing all firms or persons debarred pursuant to Section 306 (a) and (b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335 (a) and (b)), as published in the Federal Registrar from time to time; and (2) none of the Trial Personnel are debarred according to the terms and conditions of the Israeli Physicians Ordinance [New Version], 1976 or pursuant to any other applicable law.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

10.3.2. The Fund and the Principal Investigator shall provide BioCancell with the written confirmation thereof, in a form attached as Appendix B hereto.

11. Compliance with the Trial Budget and Cooperation with BioCancell Sub-Contractors

11.1. The Fund and the Principal Investigator hereby undertake to perform the Trial in accordance with the budget of the Trial, as such term is derived from Appendix C hereto (hereinafter: “the Trial Budget”) and not to deviate therefrom without the prior written approval of BioCancell in relation thereto.

11.2. The Fund hereby undertakes that any deviation from the Trial Budget without the prior written consent of BioCancell shall be born by the Fund.

11.3. The Fund and the Principal Investigator hereby undertake to fully cooperate with any and all sub-contractors nominated by BioCancell for the purpose of the Trial, including, inter alia, clinical research organizations, logistics companies, laboratories, etc.

12. Trial Documents

12.1. The Principal Investigator shall prepare and submit the Trial Documents.

12.2. The Principal Investigator shall perform all the activities specified in Appendix E hereto.

12.3. Any and all amendments to the Trial Protocol shall be performed only after securing the approval of BioCancell and the competent regulatory authority.

13.  Confidentiality

13.1. The Parties and the Principal Investigator hereby agree and undertake that they are aware that the BioCancell Data and the Trial Data (hereinafter, jointly and severally “the Confidential Information”) are confidential information, and that BioCancell has disclosed such Confidential Information to the Fund and Principal Investigator for the sole purpose of conducting the Trial.

13.2. The Parties and the Principal Investigator hereby agree and undertake that they are aware that the Confidential Information is the sole and exclusive property of BioCancell and/or any other company from the BioCancell Group. Accordingly, The Principal Investigator shall retain the Confidential Information under the strictest safeguarding and not use, disclose or divulge the Confidential Information in part or in whole, directly or indirectly, for a period of seven (7) years.

13.3. The Fund and the Principal Investigator shall maintain the confidentiality of the Confidential Information using the same degree of care used by them in relation to their own confidential information, and shall, without limitation, keep the Confidential Information in a safe and separate place and not make any copies thereof (whether in hardcopy or electronic file) unless first receiving BioCancell’s written consent.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

13.4. The Fund and the Principal Investigator hereby further undertake to limit access to the Confidential Information to the Trial Personnel and any third parties on a “need to know basis” only, and cause such Trial Personnel and third parties to accept, in writing, the undertaking of the Principal Investigator in relation to the Confidential Information under this Agreement, as a condition precedent for receipt of any part of the Confidential Information.

13.5. At the request of BioCancell, the Fund and the Principal Investigator shall forthwith return to BioCancell the Confidential Information or any part thereof.

13.6. The Fund and the Principal Investigator hereby state that they are aware of the fact that any unauthorized disclosure or use of the Confidential Information shall cause immediate and/or irreparable injury to BioCancell, and that BioCancell cannot be adequately compensated for such injury in monetary damages. Thus, in order to safeguard BioCancell from any possible breach of confidentiality, the Principal Investigator and the Fund hereby undertake that BioCancell would be permitted to obtain, from any Court or Tribunal, any temporary or permanent injunction relief, necessary to prevent such unauthorized disclosure or use or peril thereof, and hereby renounce filing and/or submitting any objection to any request by BioCancell or by any company from the BioCancell Group, relating to such temporary or permanent injunction.

13.7. For the avoidance of any doubt, it is hereby clarified that such an undertaking is supplementary to and will not prejudice any right or remedy, which is or shall be available to BioCancell under any applicable law or agreement.

	13.8.	The Fund and the Principal Investigator hereby undertake to exercise their best efforts to see to it that the Trial Personnel shall abide by the undertakings set forth in this Section 13.
	13.9.	In the event that the Fund and the Principal Investigator are required by law, regulation, rule, act or order of any governmental authority or agency to disclose Confidential Information, they shall be entitled to do so provided that it shall first notify BioCancell of any such required disclosure, so that BioCancell may seek an appropriate protective order, and limit such disclosure as far as is possible under applicable law. The Fund and the Principal Investigator will reasonably cooperate with BioCancell in its efforts to seek such a protective order. Such disclosure shall, however, not relieve the Fund and Principal Investigator of their other obligations contained herein.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

14.  Invention Rights

14.1. The Fund and the Principal Investigator hereby acknowledge that the idea and initiative for the Trial were exclusively those of BioCancell, and that the involvement of the Fund and the Principal Investigator in the Trial is strictly the consequence of their nomination by BioCancell.

14.2. The Parties and the Principal Investigator hereby irrevocably agree and undertake that the Confidential Information, except for medical records of the Subjects, is the exclusive property of BioCancell, may be freely utilized by BioCancell in any manner it sees fit. Notwithstanding the above, BioCancell shall have the right to review Subjects’ medical records to verify entries in the CRF’s. BioCancell hereby undertakes full responsibility to ensure the safekeeping of patients’ confidentiality and personal data and shall be fully responsible for taking every measure to apply this commitment.

14.3. The Parties and the Principal Investigator hereby irrevocably agree and undertake that the Invention Rights shall be the absolute and exclusive property of BioCancell and that BioCancell shall have unrestricted free right to use such Invention Rights.

	14.4.	The Fund and the Principal Investigator hereby undertake to disclose to BioCancell any and all applicable information relating to Invention Rights and exercise their best efforts with regards to registration of the Inventions Rights on the name of BioCancell and/or a name designated in writing by BioCancell, if and to the extent requested to do so by BioCancell.
	14.5.	If by operation of law or for any reason, any Invention Rights to be owned by BioCancell pursuant to this Section 14 are not automatically deemed proprietary BioCancell upon their creation, the Fund and the Principal Investigator hereby further undertake to cause the Trial Personnel to, irrevocably grant and assign all such intellectual property rights to BioCancell.

15.  Inspections

15.1. The Fund and the Principal Investigator hereby, undertake to allow the Monitors to perform monitoring visits in all sites related to the Trial, during or after the Trial, and assist the Monitors in their duties. For the avoidance of doubt, it is hereby clarified that the Monitors shall be entitled to monitor and/or inspect among others the Trial Documents and Trial Data as well as to insure compliance with the Trial Protocol.

15.2. The Fund and the Principal Investigator hereby undertake to allow the Inspectors to perform inspections of all sites related to the Trial, during or after the Trial (and each such inspection shall hereinafter be referred to as: “an Inspection”), and to assist the Inspectors in their duties, if and to the extent requested to do so by the Inspectors.

15.3. The Fund and the Principal Investigator shall immediately inform BioCancell in the event of an Inspection and/or upon gaining knowledge of any intention to perform an Inspection. The Fund and the Principal Investigator shall provide BioCancell with copies of any inquiries, correspondence or communications to or from any such Inspectors.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

16.  Publications

16.1  BioCancell covenants that it will not at any time, without first obtaining the consent in writing of the Medical Center (which consent may by refused or granted in its absolute discretion), use the Medical Center’s name or the name of the Principal Investigator or otherwise disclose the fact of their involvement in the performance of the Trial in any advertising, publicity or publication. However, BioCancell may use the name of the Fund and/or the Principal Investigator for listing the Trial on xxxxxxxxxxxxxx.xxx.

16.2  Publication of the Trial and/or its results, in whole or in part, shall be within the sole and absolute discretion of BioCancell. The Fund, the Principal Investigator or the Trial Personnel, and any employees and/or officers and/or representatives of any of the foregoing shall not publish or refer to the Trial and/or its results, in whole or in part, without obtaining the prior consent BioCancell in writing. BioCancell reserves the right to reject any such request, at its sole discretion. For the avoidance of doubt BioCancell has the right, at all times, to publish any article or data generated from the services rendered under this Agreement. Without derogating from this Section 16, BioCancell hereby undertakes to abide by the rules of publications issued by the MOH and set forth in Section 2 of Appendix D attached hereto.

17.  Reports

17.1. The Fund and the Principal Investigator hereby undertake to submit the Reports to BioCancell and/or to competent authorities, whether Israeli or foreign.

17.2. The Fund and the Principal Investigator hereby undertake to disclose in the Reports any and all data provided to them by BioCancell, in accordance with any applicable laws, rules, regulations and guidelines, including, inter alia, safety data.

17.3. The Fund will cause the Principal Investigator to provide BioCancell, within 45 (forty five) days of the end of each period of three (3) months during the period of the Trial, with a written report on the progress of the Trial in the said period.

17.4. 45 (forty five) days following the End of the Trial, the Principal Investigator shall submit to BioCancell a summary report, which shall include, in a full and detailed manner, a declaration regarding the activities performed during the Trial and the results obtained therein.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

18. Serious Adverse Event

18.1. In the event one or more of the Subjects sustains any Serious Adverse Event related to the Trial, the Principal Investigator shall inform BioCancell and the Fund Helsinki Committee and/or the Fund management and/or the authorized national health authorities.

18.2. The Principal Investigator shall report such Serious Adverse Event in the timetable and manner prescribed in the Trial Protocol and Guidelines.

18.3. In the occurrence of a Serious Adverse Event the Principal Investigator and the Fund Helsinki Committee shall be entitled to immediately cease the performance of the Trial, pending a prior notice of at least 24 hours to BioCancell regarding such decision and its execution.

18.4. In the occurrence of a Serious Adverse Event BioCancell will immediately take all measures at their disposal to evaluate the risk to the other patients and will instruct the Principal Investigator which measures to take with regard to that risk.

18.5. BioCancell has an obligation, as the trial sponsor, to notify each investigator of any Serious Adverse Events that are reported by any site during the trial that are submitted to the FDA in a safety report. Each Principal Investigator is obligated to provide these reports to the appropriate Helsinki Committee.

18.6. For the removal of doubt it is hereby clarified that should patients participating in the study are or shall be hospitalized in the course of the Study, then the Company shall reimburse the fund for any and all hospitalization expenses and hospitalization related expenses (“Hospitalization Expenses”), provided, however, that the sick funds of the patients did not cover such expenses. The Hospitalization expenses shall be paid to the Fund according to a detailed account provided to the Company by the Fund, within 30 days for receipt of the account by the Company.

19. The Legal Status of the Fund and the Principal Investigator

19.1. The Parties and the Principal Investigator hereby agree that the relationship between BioCancell, on one hand, and the Fund and the Principal Investigator, on the other hand, are that of a client and an independent contractor, with the Fund and the Principal Investigator lacking any capacity whatsoever to legally bind BioCancell to a relationship of employer-employee, principal-agent or any other legal relationship differing from that of a client and an independent contractor.

20. Term and Termination

20.1. This Agreement shall be in full force and effect as of the latter of either: (a) the date of its execution by the last Party or (b) the date the Approvals have been granted; and until the End of the Trial (and the period in which this Agreement shall be in full force and effect shall be referred to in this Agreement as “the Term of this Agreement”).

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

20.2. The Parties may bring this Agreement to an early end at any time, in writing, by prior notice of at least 30 (thirty) days, upon the occurrence of one (or more) of the following events:

20.2.1. The MOH has voided its approval granted for the performance of the Trial or has conditioned the approval by conditions which the Fund and/or the Principal Investigator, as the case may be, have notified BioCancell that they are unable to comply with.

20.2.2. The FDA has placed the Trial on clinical hold.

20.2.3. BioCancell decides upon its sole and absolute discretion to bring the Trial to an end. For the sake of good order, the Parties and the Principal Investigator hereby state and undertake that they are aware, and agree, that BioCancell is entitled to terminate this Agreement, upon its sole and absolute discretion, at any moment whatsoever; and in this case no party hereto shall have any claim whatsoever towards BioCancell and/or any other company from the BioCancell Group with regard to such early termination.

20.2.4. A Party and/or the Principal Investigator is found to be in breach of this Agreement and does not cure such breach within a period of 30 (thirty) days following receipt of a notice in writing from any of the other Parties in relation thereto.

20.2.5. A Party and/or the Principal Investigator enter into bankruptcy or liquidation proceedings or a receiver is appointed over part or all of their assets, and such proceedings are not ceased within a period of 45 (forty five) days following receipt by such Party of a written notice in relation thereto from any or all of the other Parties.

20.3. In the event of termination of this agreement the Parties and the Principal Investigator shall bring the Trial to an end as follows:

20.3.1. Any and all Confidential Information and remaining supply of Product shall be returned to BioCancell.

20.3.2. The Parties and the Principal Investigator shall cooperate in swiftly dispersing the Subjects and Trial Personnel, if the need arises, while preserving the latest Trial Data and providing as many Completed CRF’s as possible, and all to the satisfaction of BioCancell.

20.4. The obligation of the Parties and the Principal Investigator pursuant to sections 13, 14, 16, 17, and 21 shall survive termination of this Agreement.

21. Insurance and Indemnification

21.1. BioCancell has agreed to insure, in accordance with the terms and conditions set forth in Appendix D attached hereto, the Subjects, the Trial Personnel, the Principal Investigator and the Fund.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

21.2. BioCancell has agreed to indemnify the Trial Personnel the Principal Investigator, Medical Center and the Fund according to the terms of Sub-Section 21.3 below (hereinafter each of them shall also be referred to as: the “Indemnitee”) for damages arising as a direct result of their involvement in the performance of the Trial (hereinafter: the “Damages”), provided that the damages are not as a result of an expected side effect of the Products and subject to the conditions detailed herein:

21.2.1. The Damages are not caused as a result of negligence or misconduct of the Indemnitee;

21.2.2. The lndemnitee performed the Trial in accordance with the Trial Protocol and the additional requirements set in this Agreement;

21.3. Promptly after receipt by the Indemnitee of a notice of the commencement of any claim, action, suit, proceeding or investigation in respect of which indemnity may be sought pursuant to this Section 21 (hereinafter: the “Claim”), the Indemnitee shall provide a notice to BioCancell, in writing, describing in reasonable detail the facts and circumstances upon which the asserted Claim for indemnification is based, and shall thereafter keep BioCancell reasonably informed with respect thereto, BioCancell shall have the right to assume the defense of any Claim, at its sole discretion. In any event, the Indemnitee shall cooperate with BioCancell in the defense of any Claim for which BioCancell assumes the defense. BioCancell shall not be liable for the settlement by the lndemnitee of any Claim affected without the consent of BioCancell. BioCancell shall be entitled to enter into any settlement of a Claim at its sole discretion.

22. Notices.

22.1. Notices to be given by one Party to another shall be in the English language, and shall be deemed properly given if reduced to writing and transmitted to the Party’s address appearing on the first page of this Agreement, by air courier or by certified registered mail - all to be effective 3 (three) days after their sending date, or by facsimile with confirmation receipt - to be effective at the first business day following the date of transmission.

22.2. However, a notice shall be considered properly given, only in case a copy thereof was communicated as follows:

Notice to BioCancell	Notice to Fund
BioCancell Therapeutics Ltd.	Medical Research Development and
Xxxx Science Center, 8 Hartom St.	Health services
Jerusalem, 00000 Xxxxxx	Sheba Medical Center
Attn: Xxx Xxxxxx	Xxx Xxxxxxxx, 00000 Xxxxxx
Director, Strategic Alliances	Attn: Xxxx Xxxxxx Xxx,
Telephone:        x000-0-000-0000	Deputy Director for R&D
Facsimile:          x000-0-000-0000	Tel: 00-0000000
	Fax: 00-0000000

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

22.3. The addresses of the Parties, listed in page 1 of this Agreement, shall be subject to any change of such address notified in writing by one Party to the other, according to the procedure stipulated in this Section.

23. Miscellanies

23.1. Expenses of the Parties. Each Party and the Principal Investigator shall bear all its own expenses, including the expenses of its attorneys, in connection with the negotiation, execution and performance of this Agreement.

23.2. Waiver and forbearance. No rights of any Party shall be prejudiced or restricted by any indulgence or forbearance, to any other person or entity, and no waiver by any Party in respect of any breach shall operate as a waiver in respect of any subsequent breach.

23.3. Governing law and jurisdiction. This Agreement shall be exclusively governed by the Laws of the State of Israel. Any and all disputes arising hereunder shall be resolved by a competent court having jurisdiction over such matters in the Tel-Aviv Jaffn District, Israel

23.4. Assignment. This Agreement shall not be assigned, without the prior written consent of all of the other Parties, save for an assignment of rights by BioCancell to any company within the BioCancell Group

23.5. Counterparts. This Agreement and any amendment hereto may be executed in multiple counterparts, each of which shall be deemed an original agreement and all of which shall constitute one and the same agreement.

23.6. Amendments. Modification or amendment to this Agreement shall only be valid if performed by a written instrument, signed by all Parties to this Agreement.

23.7. Severability. If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable, that determination shall not affect any other provision of this Agreement, and each such other provision shall be construed and enforced as if the invalid, illegal, or unenforceable provision were not contained herein.

[Remainder of page left intentionally blank. Signature page follows.]

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the undersigned hereby warrants and represents that he or she has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement.

IN WITNESS WHEREOF, the parties have executed this Agreement as at the date first above written:

BioCancell Therapeutics Ltd.			Medical Research Development and Health Services, Sheba Medical Center
By:	/s/ Xxx Xxxxx		By:	/s/ Xxxx. X. Xxx, M.D. Ph.D
Print Name: Xxx Xxxxx			Print Name:	Xxxx. X. Xxx, M.D. Ph.D
Title: CEO			Title:	Head - R & D Sheba Medical Center Tel Hashomer Israel
By:	/s/ Xxxxxxxx Xxxxx		By:	[Illegible]
Print Name: Xxxxxxxx Xxxxx			Print Name:	[Illegible]
Title: VP Clinical Development			Title:	[Illegible]
				14.7.08

I the undersigned, Xxxxx X. Xxxxx, hereby declare and confirm that I have read and understood the Agreement. I hereby agree to be appointed as the Principal Investigator of the Trial on behalf of the Fund, and accept and undertake to comply with all the terms, conditions, provisions, instructions and stipulations set forth in the Agreement, including, without limitation, provisions referring to the Parties.

/s/ Z. A. Dotan

The Principal Investigator

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Appendix A

The Trial Protocol

See attached separately

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Appendix B

The Trial Personnel Clearance

An Undertaking with regard to a Clinical Trial’s Personnel

We, the undersigned, hereby warrant and undertake in relation of clinical trial bearing protocol number BC-07-01, researching “Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients with Intermediate-Risk Superficial Bladder Cancer”, that we have not, we do not and we will not use nor employ, in any capacity, the services of any person debarred under Section 306 (a) or (b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335 (a) and (b)), or debarred under the Israeli Physicians Ordinance [New Version], 1976 or pursuant to any other applicable law.

/s/ Z. A. Dotan		Xxxx. X. Xxx, M.D. Ph.D Head - R & D Sheba Medical Center Tel Hashomer Israel
The Principal Investigator		The Fund

14.2.08

Date

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Appendix C

The Consideration

1. Terms and Definitions

In this Appendix C terms shall have the meaning assigned to them in the Agreement. The following terms shall have the meanings assigned to them hereunder:

Complete Screening		A Screening of a Subject in which all examinations and/or tests and/or treatment and/or evaluations included in the Screening process, as detailed in the Trial Protocol, have been performed and the data collected and registered in the CRF
Complete Evaluation Visit or Complete Treatment Visit		A Visit of a Participating Subject in which all examinations and/or tests and/or treatment and/or evaluations scheduled for the visit have been performed, as detailed in the Trial Protocol, and the data collected and registered in the CRF
Evaluation Visit		Any Visit, as defined below, of visits 7, 11, 15, and 19 as these visits are numbered and defined in the Trial Protocol.
Participating Subject		A Subject who that has undergone Screening, as defined below, and was determined to meet the requirements specified in the Trial protocol and who is participating in the Trial according to the terms and conditions of the Trial Protocol
Screening		A series of tests and examinations as defined in table 4 of the Trial Protocol designed to evaluate a Subject’s suitability for participating in the Trial, as detailed in the Trial Protocol.
Treatment Visit		Any Visit, as defined below, of visits 1-6, 8-10, 12-14, and 16-18 as these visits are numbered and defined in the Trial Protocol.
Visit		Any one of the scheduled nineteen (19) visits of a Participating Subject as detailed in table 4 and 5 of the Trial Protocol.

2. The Consideration

2.1. In consideration for the performance, in good faith, by the Principal Investigator and the Fund, of all of their undertakings under  this Agreement, BioCancell hereby undertakes to pay to the Fund the following amounts:

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Visit #		Procedure		Total costs per visit (NIS)
Screening		Urine cytology Video cystoscopy Histology & Pathology Doctor’s fee Study nurse Study coordinator TUR		3,150
Visit # 1		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 2		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 3		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 4		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 5		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 6		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 7		Urine cytology Video cystoscopy Histology & Pathology Doctor’s fee Study nurse Study coordinator TUR		2,650
13,300

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Visit # 8		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 9		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 10		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 11		Urine cytology Video cystoscopy Doctor’s fee Study nurse Study coordinator		1,510
Visit # 12		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 13		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 14		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 15		Urine cytology Video cystoscopy Doctor’s fee Study nurse Study coordinator		1,510
Visit # 16		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Visit # 17		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 18		Doctor’s fee Study nurse (Drug administration & blood sampling) Study coordinator		1,250
Visit # 19		Urine cytology Video cystoscopy Doctor’s fee Study nurse Study coordinator		1,150
Total per continued treatment period (if no recurrence)				15,780
Total per first treatment period & continued treatment period				29,080
General		Unscheduled Video cystoscopy		370
General		Unscheduled TUR		960
Pharmacy				500 US $

* Blood work and Urine analysis will be perform by an external central Lab (the costs will be covered by the sponsor).

3. Limitation of Payments

3.1. For the avoidance of doubt, it is hereby declared and agreed that BioCancell shall not pay any additional payments or any other amounts, which are not clearly mentioned and specified in section 2 above.

3.2. It is further clarified that the amounts specified in section 2 above include payment by BioCancell for all services rendered from the Fund including but not limited to office services, Trial Personal required for performing the Trial including the Principal Investigator, physicians, nurses, receptionists and study coordinator, use of the Fund’s facilities, and all tests, procedures, examinations and evaluations as detailed in the Trial protocol.

3.3. The considerations do not include cost of analysis of hematology and chemistry samples which will be performed by BioCancell’s sub-contractor/s.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

4. Terms of Payment

4.1. The Fund shall send an invoice at the end of each calendar quarter (31/3, 30/6, 30/9, and 31/12) detailing the Complete Screening, Complete Treatment Visits and Complete Evaluation Visits (together hereinafter: “Complete Visits”) performed as well as on which Subjects or Participating Subjects the relevant Complete Visit was performed.

4.2. Payments detailed in section 2 shall be conditioned upon payment for Complete Visits and shall be included in the first invoice sent by the Fund.

4.3. Payment shall be maid by BioCancell within 30 (thirty) days of receipt of the Fund’s invoice.

	4.4.	All Payments shall be performed in the last day of the calendar year during which the relevant payment date occurred. (Occurrence of the relevant payment date shall be at the termination and completion of the stage and conditions of which entitles the Fund for payment according to this Appendix C).
	4.5	Immediately upon receiving the payment as per the issued invoice the Fund will provide BioCancell with a receipt approving the payment.

5. Currency of Payments

All of the payments subject of this Appendix C shall be performed by BioCancell to the Fund in NIS (New Israel Shekel).

6. General Observations and Clarifications

For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell:

6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Fund, prior to the commencement of the Trial.

6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Fund, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion:

6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRF’s have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Fund by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”)

6.2.2. Order the Fund, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. The Fund hereby undertakes that it shall pay the Return Amount, as specified above, and renounces any contentions and/or claims whatsoever in relation thereto.

6.2.3. In the event that the Return Amount shall exceed the Remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Fund.

6.3. No advance payments would be performed by BioCancell to the Fund.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Appendix D

Schedule 4 of the Guidelines

Title of the trial: “Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients with Intermediate-Risk Superficial Bladder Cancer”
The protocol name and number: BC-07-01
Name of the investigational product: DTA-H19/PEI
Name of the Principal Investigator:	Department: Urology
Name of the medical institution:
The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx Xx., Xxxxxxxxx 00000, Xxxxxx

1. Sponsor undertaking

The Sponsor undertakes to act in accordance with the local and international law for clinical trials, and in particular with regard to the following issues:

1.1.1. Responsibility for the safety and good order of the investigational product;

1.1.2. Supply of information regarding the trial;

1.1.3. Notice to the Ministry of Health regarding the performance of a multicenter trial in Israel;

1.1.4. Monitoring the trial process;

1.1.5. Safety reports;

1.1.6. Accountability in respect of the investigational product;

1.1.7. Retention of documents.

2. The Sponsor undertakes that if it shall decide to publish the results of the clinical trial in scientific literature, it shall publish them in full and without taking matters out of their context.

3. Insurance:

3.1. The Sponsor undertakes to insure its legal liability pursuant to the laws of the State of Israel against claims that may be filed by subjects in the clinical trial and/or third party claims - all in connection with the clinical trial, whether in the period of conducting the clinical trial or thereafter. The insurance shall be extended to include the legal liability of the medical institution and/or the clinical trial personnel and/or the Principal Investigator (hereinafter referred to as “the parties conducting the trial”) deriving from their involvement in the conduct of the clinical trial, subject to an exception of an act committed negligently or an intentional deviation from the clinical trial protocol.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

3.2. The Sponsor shall be given notice of any claim or any potential claim immediately after such comes to the knowledge of the medical institution or the Principal Investigator.

3.3. The Principal Investigator, the medical institution and its employees shall give the Sponsor, upon its written request, reasonable support in any event of a claim that may be filed against it as aforesaid.

4. The Sponsor undertakes to supply the medical institution with the investigational product throughout the period of the clinical trial until the conclusion thereof, free of charge. Furthermore, the Sponsor undertakes to pay all additional costs deriving from the conduct of the clinical trial, provided that such costs do not derive from the regular medical treatment of the sickness.

5. If after the termination of the clinical trial it is ascertained and recommended by the Principal Investigator that the welfare of the patient participating in the clinical trial necessitates continuation of his treatment with the investigational product and there is no other appropriate alternative medical treatment, the Sponsor undertakes to also continue supplying the investigational product, without charge, after the termination of the clinical trial for a period of three years, except in one of the following cases:

5.1. The investigational product was approved for marketing in the State of Israel after its registration for its requested scope and it can be obtained from the sick fund with which the patient is insured.

5.2. The development of the product was discontinued or the results of the clinical trials were unsuccessful.

5.3. The administration of the investigational product for the said protracted period is likely to harm the patient’s health, since there is insufficient information regarding the safety of the product administered over the long term.

5.4. Where the investigational product is not a medical preparation, such as: cosmetic products / food / food additive / herbal remedy.

The decision as to the continuation of administering the investigational product is given to the medical institution’s Helsinki Committee (“the Helsinki Committee”), that is entitled to re-examine its determination from time to time. The Principal Investigator and the Sponsor have a right of appeal against such decision to the Ministry of Health’s director-general or such person as empowered by him in such regard.

6. The continued administration of the investigational product after termination of the clinical trial is subject to the following terms and conditions:

6.1. The continued treatment shall be given within the context of an orderly monitoring protocol that shall be written by the Principal Investigator and approved by the Sponsor and the Helsinki Committee.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

6.2. The Principal Investigator is responsible for continuing to routinely monitor the subject’s medical condition and to report to the Helsinki Committee any exceptional events that occur during the ongoing treatment, as is the norm in clinical trials.

The principal investigator shall report to the Helsinki Committee at least once a year as to the progress of the subject’s treatment.

The medical institution in which the ongoing treatment shall be given shall attend to appropriate insurance cover for the liability of the medical institution and the Principal Investigator vis-a-vis the patient, in respect of the continuation of administering the investigational product after the termination of the clinical trial.

7. This Appendix constitutes an integral part of the agreement between the company sponsoring the clinical trial and the medical institution.

BioCancell Therapeutics Ltd.			Sheba Medical Center, Tel Hashomer
By:	/s/ Xxx Xxxxx		By:	/s/ Xxxx. X. Xxx, M.D. Ph.D
Print Name: Xxx Xxxxx			Print Name:	Xxxx. X. Xxx, M.D. Ph.D
Title: CEO			Title:	Head - R & D Sheba Medical Center Tel Hashomer Israel
By:	/s/ Xxxxxxxx Xxxxx		By:
Print Name: Xxxxxxxx Xxxxx			Print Name:
Title: VP Clinical Development			Title:
				14.2.08

I the undersigned,    Z. A. Dotan     , hereby declare and confirm that I have read and understood this Appendix D.

/s/ Z. A. Dotan

The Principal Investigator

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

Appendix E

The Trial Documents and Related Activities

The Trial Documents shall include, inter alia, all the documents set forth in the Guidelines, as well as the documents specified hereunder.

Any and all terms not specifically defined in this Appendix shall have the meaning attributed to them in the Agreement.

Prior to the initiation of the Trial:

1. The executed signature page of the Trial Protocol; and

2. Investigator Brochure; and

3. The current curriculum vitae of the Principal Investigator; and

4. The list of all sub-investigators, all of which necessarily being listed on either the FDA form no. 1572, or on the Principal Investigator’s Statement Form; and

5. The written approval of the Medical Center Helsinki Committee, indicating that it has reviewed and approved the Trial Protocol; and

6. The written approval of the MOH with regards to the content of all publicity and advertisements, related to the Trial, which are to be performed prior to the commencement of the Trial; and

7. A list of all participants in the Helsinki Committee, convened in relation to the Trial (hereinafter: “the Helsinki Committee”); and

7.1. Should the Principal Investigator be a member of the Helsinki Committee, the written Statement of the chairman of the Helsinki Committee confirming that the Principal Investigator did not participate in the voting, relating to the Trial, during the hearing of the said Helsinki Committee; and

7.2. A financial disclosure form, confirming that the Principal Investigator holds no financial interests in BioCancell.

While conducting the Trial:

1. A review of all the Trial Documents and verification the accuracy and completeness thereof in relation to the source documents, on which the above documents were based; and

2. Report to the Medical Center Helsinki Committee of any Severe Adverse Events, as such terms are defined in the Trial Protocol, to the Subject(s), in accordance with the Guidelines; and

3. Report to the Medical Center Helsinki Committee of any deviation from the Trial Protocol; and

4. Maintain adequate records of Subjects identification, clinical observations, as well as study drug receipt and dispensation (hereinafter: “the Records”), in accordance with any applicable laws, rules, regulations and guidelines, as amended from time to time. In any event, the Principal Investigator and BioCancell shall maintain the Records for a period of no less than 15 (fifteen) years following the end of the Trial.

0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: x000-0-000-0000 Fax: x000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

5. Compare the data in the CRF with the source documents relating to each subject participating in the Trial, and confirm the accuracy of the CRF; and

6. Maintain a log, documenting the Product(s) provided to each subject during the Trial; and

7. Report no later than 7 (seven) days before additional quantities of Product(s) are required to proceed with the Trial.

8. Complete all CRFs

9. Re-validate the approval of the relevant Helsinki Committee to the Trial, within a reasonable time prior to its expiration date.

10. A written detailed periodic report on the progress of the Trial in the said period (section 17.3 of the Agreement).

At the end of the Trial:

1. All Completed CRFs;

2. A summary report, which shall include, in a full and detailed manner, a declaration regarding the activities performed during the Trial and the results obtained therein (section 17.4 of the Agreement).